Evidence map›Paper›PMID 26674355›Full record

ArticlePloS one2015

The Cytoprotective Effect of Hyperoside against Oxidative Stress Is Mediated by the Nrf2-ARE Signaling Pathway through GSK-3β Inactivation.

Hai-Yan Xing, Yong-Qing Cai, Xian-Feng Wang, Lin-Li Wang, Pan Li, Guan-Ying Wang, Jian-Hong Chen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 72 citations in OpenAlex.

  1. Review
  2. Hyperoside AlleviatesPolish journal of microbiology · 2025
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Reciprocal REGOxidative medicine and cellular longevity · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Frontiers in pharmacology · 2021
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. PYP1-4 peptide fromExperimental and therapeutic medicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hai-Yan XingDepartment of Pharmacy, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Yong-Qing CaiDepartment of Pharmacy, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Xian-Feng WangDepartment of Pharmacy, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Lin-Li WangDepartment of Pharmacy, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Pan LiDepartment of Pharmacy, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Guan-Ying WangDepartment of Pharmacy, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Jian-Hong ChenDepartment of Pharmacy, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
Daping Hospital · CNArmy Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycogen synthase kinase-3β (GSK-3β) acts as a negative regulator of NF-E2 related factor 2 (Nrf2) by inducing Nrf2 degradation and nuclear export. Our previous study demonstrated that the flavonoid hyperoside elicits cytoprotection against oxidative stress by activating the Keap1-Nrf2-ARE signaling pathway, thus increasing the expression of antioxidant enzymes, such as heme oxygenase-1 (HO-1), superoxide dismutase (SOD) and catalase. However, the role of GSK-3β in hyperoside-mediated Nrf2 activation is unclear. Here, we demonstrate that in a normal human hepatocyte cell line, (L02), hyperoside is capable of inducing the phosphorylation of GSK-3β at Ser9 without affecting the protein levels of GSK-3β and its phosphorylation at Thr390. Lithium chloride (LiCl) and short interfering RNA (siRNA)-mediated inhibition of GSK-3β significantly enhanced the ability of hyperoside to protect L02 liver cells from H2O2-induced oxidative damage, leading to increased cell survival shown by the maintenance of cell membrane integrity and elevated levels of glutathione (GSH), one of the endogenous antioxidant biomarkers. Further study showed that LiCl and siRNA-mediated inhibition of GSK-3β increased hyperoside-induced HO-1 expression, and the effect was dependent upon enhanced Nrf2 nuclear translocation and gene expression. These activities were followed by ARE-mediated transcriptional activation in the presence of hyperoside, which was abolished by the transfection of the cells with Nrf2 siRNA. Furthermore, the siRNA-mediated inhibition of Keap1 also enhanced hyperoside-induced Nrf2 nuclear accumulation and HO-1 expression, which was relatively smaller than the effects obtained from GSK-3β siRNA administration. Moreover, Keap1 siRNA administration alone had no significant effect on the phosphorylation and protein expression of GSK-3β. Collectively, our data provide evidence that hyperoside attenuates H2O2 -induced L02 cell damage by activating the Nrf2-ARE signaling pathway through both an increase in GSK-3β inhibitory phosphorylation at Ser9 and an inhibition of Keap1 and that hyperoside-mediated GSK-3β inhibition exhibits more significant effects.

Indexed as

Oxidative StressResponse ElementsSecond Messenger SystemsAntioxidantsCell LineGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHepatocytesHumansNF-E2-Related Factor 2QuercetinAntioxidantsGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGSK3B protein, humanhyperosideNFE2L2 protein, humanNF-E2-Related Factor 2Quercetin

Identifiers

PMID26674355
PMCPMC4682950
OpenAlexW2286917400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.